Références

Information sur le cancer / Types de cancer / Os / Recherche

Amela E, Bompas E, Le Cesne A, Tresch E, Italiano A, Piperno-Neumann S, Collard O, et al. A phase II trial of sorafenib (SO) in advanced chordoma patients (pt). (2015). ASCO 2015 Annual Meeting. Alexandria, VA: American Society of Clinical Oncology. Abstract 10520.

Broto JM, Redondo A, Valverde CM, Vaz Salgado MA, Mora J, del Muro XG, Sancho Marquez MP, et al. Phase II trial of gemcitabine plus rapamycin as second line in advanced osteosarcoma: A Spanish Group for Sarcoma Research (GEIS) Study. (2015). ASCO 2015 Annual Meeting. Alexandria, VA: American Society of Clinical Oncology. Abstract 10530.

Carcano FM, dos Santos LV, Vidal DO, Lopes LF, da Silveria Nogeira Lima JP. Prognosis value of HER2 in osteosarcomas: A systematic review with meta-analysis. (2015). ASCO 2015 Annual Meeting. Alexandria, VA: American Society of Clinical Oncology. Abstract e21504.

Chawla NS. Sustained response of complex giant cell tumors with denosumab: single center 8-year experience. (2015). ASCO 2015 Annual Meeting. Alexandria, VA: American Society of Clinical Oncology. Abstract 10528.

Huang JF, Du WX, Chen JJ. Elevated expression of matrix metalloproteinase-3 in human osteosarcoma and its association with tumor metastasis. (2016). Journal of BUON. 21(1): 235-243.

Liu Y, Teng Z, Wang Y, Gao P, Chen J. Prognostic significance of surviving expression in osteosarcoma patients: a meta-analysis. (2015). Medical Science Monitor. International Scientific Information, Inc. 21:2877-2885.

Lugowska I, Mikula M, Teterycz P, Kulecka M, Kluska A, Piatkowska M, et al. IDH mutations to predict shorter survival in chondrosarcoma. (2016). ASCO 2016 Annual Meeting. Alexandria, VA: American Society of Clinical Oncology. Abstract 11024.

Palmerini E, Picci P, Marchesi E, Staals EL, Cesari M, Longhi A, Paioli A, et al. High dose ifosfamide in metastatic high-grade osteosarcoma, after failure of standard multimodal chemotherapy. (2015). ASCO 2015 Annual Meeting. Alexandria, VA: American Society of Clinical Oncology. Abstract 10527.

van de Luijtgaarden AC, Kapusta L, Bellersen L, Bokkerink JP, Kaal SE, Versleijen-Jonkers YM, et al. High prevalence of late adverse events in malignant bone tumour survivors diagnosed at adult age. (2014). Netherlands Journal of Medicine. 72(10): 516-522.

Yu H, Yu J, Ren Y, Yang Y, Xiao X. Serum CEACAM1 level is associated with diagnosis and prognosis in patients with osteosarcoma. (2016). PLoS One. 11(4): e0153601.

×
×